Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Half Yearly Report and Accounts

Friday, March 1, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has reported significant progress in its clinical studies, including the initiation of a Phase 1/2a clinical trial for BetaBart (RV-01). The company has also received IND approval from the US FDA for a therapeutic study targeting B7H3. Furthermore, positive updates have been shared across four of its programs, indicating a strong pipeline.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has initiated a Phase 1/2a clinical study.
  • Positive clinical updates have been provided across four programs.
  • The company received IND approval from the US FDA for a new therapeutic study.

Full Press Release Details

• Announcements
• Periodic Reports , Price Sensitive
• March 1, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• November 22, 2023
• Announcements
• November 16, 2022
• Announcements
• June 12, 2025
• Announcements
• November 8, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the focus of the Phase 1/2a clinical study?

The Phase 1/2a clinical study focuses on BetaBart (RV-01) targeting B7H3.

What recent approvals has Radiopharm received?

Radiopharm Theranostics received IND approval from the US FDA for a new therapeutic study.

How many programs received positive updates?

Positive clinical updates were provided across four programs.

When was the half yearly report announced?

The half yearly report was announced on March 1, 2024.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart Phase 1/2a clinical trials IND approval
Last updated: Mar 1, 2024